Krystal Biotech, Inc.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Operating Activities | ||
| Net income | $153,431 | $43,680 |
| Adjustments to reconcile net income to net cash provided by operating activities | ||
| Deferred income taxes | (24,680) | — |
| Depreciation | 4,162 | 4,603 |
| Amortization (accretion) on marketable securities | 139 | (1,535) |
| Amortization of operating lease right-of-use assets | 627 | 556 |
| Stock-based compensation expense, net | 40,750 | 35,771 |
| Realized gain on investments | (5,549) | (4,427) |
| Other, net | 395 | 725 |
| Changes in operating assets and liabilities | ||
| Accounts receivable, net | (24,616) | (55,257) |
| Inventory | (5,228) | (5,386) |
| Prepaid taxes | (10,103) | (646) |
| Prepaid expenses and other current assets | (4,311) | (1,979) |
| Lease liability | (413) | (617) |
| Other long-term liabilities | 1,718 | 761 |
| Accounts payable | 1,009 | 1,602 |
| Accrued expenses and other current liabilities | 8,318 | (2,092) |
| Accrued rebates | 18,958 | 23,568 |
| Accrued litigation settlement | (31,250) | 31,250 |
| Net cash provided by operating activities | 123,357 | 70,577 |
| Investing Activities | ||
| Proceeds from disposal of assets | 435 | — |
| Purchases of property and equipment | (9,812) | (3,437) |
| Purchases of available-for-sale securities | (350,078) | (314,268) |
| Maturities of available-for-sale securities | 289,875 | 238,044 |
| Net cash (used in) investing activities | (69,580) | (79,661) |
| Financing Activities | ||
| Proceeds from exercise of stock options | 6,972 | 29,972 |
| Taxes paid for employee tax withholding related to restricted stock units | (12,121) | (4,181) |
| Taxes paid related to settlement of restricted stock awards | (1,812) | (1,205) |
| Net cash (used in) provided by financing activities | (6,961) | 24,586 |
| Effect of exchange rate changes on cash and cash equivalents | 923 | 136 |
| Net increase in cash and cash equivalents | 47,739 | 15,638 |
| Cash and cash equivalents at beginning of period | 344,865 | 358,328 |
| Cash and cash equivalents at end of period | $392,604 | $373,966 |
| Supplemental Disclosures of Non-Cash Activities | ||
| Unpaid purchases of property and equipment included in accounts payable and accrued expenses | $623 | $8,292 |
| Initial recognition of right-of-use assets | $1,794 | $— |
| Supplemental Cash Flow Information | ||
| Income taxes paid | $13,876 | $5,150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.